We have determined the role of nitric oxide (NO)-mediated tumor cell killing in the treatment of an animal model of murine ovarian carcinoma grown in the peritoneum with a combination of cisplatin and cationic liposomes containing an expression vector for interferon-␥ (IFN-␥). The approach was to determine whether the therapy was effective in mice homozygous for a disrupted inducible NO synthase (iNOS) allele; these mice were unable to produce NO in response to IFN-␥. iNOS (Ϫ/Ϫ) mice treated with both cisplatin and liposomal IFN-␥ gene did not produce a significant amount of NO in ascites (12.1 Ϯ 4.5 M), although they expressed a high level of IFN-␥ (9002 Ϯ 723 U/mL of ascitic fluid). As a result, mice died of tumors within 11-62 days. However, wild-type mice treated with both cisplatin and liposomal IFN-␥ gene produced a significant amount of NO in ascites (113.7 Ϯ 17.9 M) with a high level of IFN-␥ gene expression (9350 Ϯ 1254 U/mL of ascitic fluid) and were free of tumors for at least 80 days. This result confirmed that NO was a direct mediator of IFN-␥ cytotoxicity.
C ationic liposome-mediated transfection (lipofection) is an efficient method for direct gene transfer in vitro and in vivo that has emerged as an important experimental means to gene therapy of cancer. 1 Direct injection of a plasmid DNA/liposome complex into the tumor (in situ lipofection) has been reported in animal models 2 and in clinical trials. 3 Ovarian cancer is the fourth leading cause of death among cancers in woman. Cisplatin, a DNA crosslinking agent, is one of the few drugs routinely used in treating ovarian carcinoma, but its clinical effectiveness is limited by the emergence of drug resistance in tumor cell populations. Thus, there is a clear need for new treatment modalities to overcome the problem of drugresistant ovarian cancer.
Endogenous nitrogen and oxygen free radicals are involved in many biological processes including mediators of damage in the immune response to tumors. Nitric oxide (NO), produced from activated macrophages by immunostimulant(s), is a major effector for tumor cell killing and induces apoptosis. Immunostimulants such as interleukins, tumor necrosis factor (TNF), and interferon (IFN) have potent antitumoral activities, alone or in combination with cisplatin. 4, 5 We demonstrated previously that an aggressive syngeneic murine ovarian carcinoma was completely treated with the cisplatinbased lipofection of IFN-␥ gene through enhanced long-lasting production of IFN-␥ only in tumor localized sites, which was prevented by the inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine. 6 To expand this observation, we have determined whether a combination therapy of cisplatin and cationic liposomes containing an expression vector for IFN-␥ is effective in iNOS knockout (iNOSKO) mice, which are unable to produce NO in response to IFN-␥.
MATERIALS AND METHODS

Materials
Cisplatin was purchased from Sigma (St. Louis, Mo). [ 14 C] chloramphenicol was obtained from ICN (Irvine, Calif).
Preparation of plasmid DNA
Bacterial chloramphenicol acetyltransferase (CAT) as a reporter gene was used to measure its expressions 7 in ascitic tumors. Murine IFN-␥ (mIFN-␥) as a therapeutic gene was used to measure its expression levels in ascites and its therapeutic effect. pUCCMVCAT (5.1 kb) is a pUC18-based plasmid containing the full-length CAT cDNA downstream from the immediate early promoter of the human cytomegalovirus element (a generous gift of H. Farhood and N. Serbina, University of Pittsburgh, Pittsburgh, Penn). A mIFN-␥ cDNA expression vector, pBCMGNeo-mIFN-␥ (15.4 kb), was constructed by inserting cDNA-encoding mIFN-␥ into the bovine papilloma virus-based plasmid BCMGNeo 8 (generously provided by Dr. D. Pardoll, Johns Hopkins University, Baltimore, Md). Plasmid DNA was transformed in DH5␣ and was purified using an endo-free Qiagen Giga kit (Qiagen, Valencia, Calif). The yield of pUCCMVCAT (high-copy plasmid) was 8 mg per 2.5-L culture, whereas the yield of pBCMGNeomIFN-␥ (low-copy plasmid) was 3 mg per 5-L culture. The purity was confirmed by the A 260 /A 280 ratio and on agarose gel. The level of endotoxin was Ͻ0.1 EU/g DNA.
Animals
Female C57BL6/J wild-type (C57BL6 WT) and homozygous iNOS (NOS2) knockout (C57BL6 iNOSKO) mice weighing 20 -23 g were used in all experiments. C57BL6 iNOS KO mice were generously provided by Dr. John Mudgett (Merck Research Laboratory, Rahway, NJ). These mice were derived from the original C57BL6/J iNOSKO ϫ 129SvEv lines generated at Merck. 9 WT controls were obtained by breeding C57BL6J mice (The Jackson Laboratory, Bar Harbor, Me) with 129SvEv mice (Taconic, Germantown, NJ). Animal care was in accordance with the institutional guidelines.
Tumor cells
Murine ovarian teratocarcinoma (MOT) was obtained from Dr. F. M. Sirotnak (Memorial Sloan Kettering, New York, NY). 10, 11 A murine germ-cell tumor MOT grew as rapidly in an allogeneic C57BL6/J mouse as it did in a syngeneic C3HeB/ FeJ as malignant ascites.
In situ lipofection
MOT ascites (2 ϫ 10 6 cells/0.2 mL) were injected into the peritoneum of C57BL6/J WT or C57BL6/J iNOSKO mice to induce the formation of an ascitic tumor using a 21-gauge needle as described previously. 6 At 7 days after tumor transplantation, a single dose of either phosphate-buffered saline (PBS) or cisplatin (7 mg/kg) (Sigma) was injected intraperitoneally (i.p.) into mice. After 1 week, mice were injected i.p. with a complex of a DNA and liposomes. Cationic DC-chol liposomes were composed of 3␤(N-[NЈ,NЈ-dimethyl aminoethane]carbamoyl)cholesterol (DC-chol) and dioleoyl phosphatidylethanolamine (DOPE) (DC-chol:DOPE, 3 mol:2 mol). 12 A total of 200 g of plasmid DNA in 1ϫ TE buffer (1 g/l) was mixed with 200 nmol of DC-chol liposome in water (2 nmol/ L). This complex was then injected directly into the peritoneum of MOT-bearing mice using a 27-gauge needle. The animals were sacrificed 3 days later to examine the expression of the injected genes.
Radiometric assay of CAT activity
The ascitic tumors taken from animals were homogenized, lysed by three freeze-thaw cycles, heated at 65°C for 10 minutes, and centrifuged at 16,000 ϫ g for 10 minutes. The protein concentration of the extracts was measured with Bio-Rad reagent (Bio-Rad, Richmond, Calif). The protein extract of each tumor (100 g) was then assayed for CAT activity using [ 14 C] chloramphenicol as a substrate. 13 The acetylated and nonacetylated forms of chloramphenicol were quantified with a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif). CAT activity was expressed as the percentage of conversion; acetylated forms were divided by acetylated plus nonacetylated forms.
IFN-␥ assay
The IFN-␥ assay was performed as described previously.
14 The ascites collected from animals were centrifuged at 12,000 rpm for 20 minutes at 4°C to obtain ascitic fluids. The ascitic fluids were serially diluted with culture medium. A series of diluted ascitic fluid or standard mIFN-␥ (0 -100 U/mL) was added to RAW 264.7 cells (1 ϫ 10 5 cells/200 L/well), which were seeded and incubated for 4 -6 hours. After incubation for 24 hours at 37°C in a CO 2 incubator, the medium was collected for the measurement of nitrite accumulation at A 550. The IFN-␥ concentration was calculated from the nitrite concentration using the standard curve with mIFN-␥.
Determination of NO synthesis in vivo
The determination of NO synthesis was performed as described previously. 15 Briefly, the ascites collected from animals were centrifuged at 14,000 rpm for 10 minutes at 4°C to obtain ascitic fluids. The NO concentration (total NO 2 Ϫ plus NO3) in the ascitic fluids was determined by reducing the NO 3 Ϫ to NO 2 Ϫ with Aspergillus nitrate reductase followed by Griess assay. The nitrite concentration was measured at 550 nm, and the total nitrite plus nitrate concentration was calculated from the standard curve as described previously. 15 Gene therapy in C57BL7 WT and C57BL6 iNOSKO mice
Gene therapy in C57BL7 WT and C57BL6 iNOSKO mice was performed as described previously. 6 MOT cells (2 ϫ 10 6 cells/0.2 mL ascites) were transplanted i.p. into the peritoneum of C57BL6 WT or C57BL6 iNOSKO mice. After 4 days, mice were treated i.p. with either PBS or cisplatin (7 mg/kg). The i.p. treatment of mice with liposomal IFN-␥ gene was initiated 5 days after a cisplatin injection to allow for the increase in NO synthesis 16 and was continued once every 5 days for 4 weeks. Afterward, mice were maintained without further treatment. A total of 200 g of DNA was mixed with 200 nmol of liposomes. Animals were divided into eight groups. Groups 1 and 2 received PBS and liposomal empty vector, groups 3 and 4 received PBS and liposomal pBCMGNeo-mIFN-␥ DNA, groups 5 and 6 received cisplatin and liposomal empty vector, and groups 7 and 8 received cisplatin and liposomal pBCMGNeo-mIFN-␥ DNA. Groups 1, 3, 5, and 8 were WT mice. MOT cells (0.2 mL of ascites) taken from the C3HeB/FeJ ascites were injected into the peritoneum of the mice using a 21-gauge needle and examined for tumor growth by monitoring body weight for 30 days.
*Number of mice with tumors per number of total mice injected with MOT; 1, 2, and 3 indicate three different experiments.
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Groups 2, 4, 6 and 8 were KO mice. Because tumor-bearing mice all die once their body weight reaches ϳ36 g, a mouse with 34 g of body weight was considered as a dead point and thus sacrificed.
Statistics
Statistical comparisons were made by the unpaired Student's t test using the Statworks program (Macintosh). Significance was determined as P Ͻ .05.
RESULTS
To eliminate our first concern relating to the use of an allogeneic system for our studies, as the MOT cell line was originally established from C3H mice, we tested MOT ascitic tumor growth in allogeneic C57BL6 WT and iNOSKO mice. As shown in Table 1 , the tumor incidence in C3H mice was 94.4%, compared with 87.5% in C57BL6 WT mice and 88.9% in iNOSKO mice. The growth rates of murine ovarian carcinoma in syngeneic C3H mice and allogeneic mice were observed to be very similar (data not shown). This means that the growth of MOT ascitic tumors in both allogeneic and syngeneic mice was comparable for our therapy experiments. We reported previously that the sensitization of the MOT ascitic tumors by cisplatin pretreatment was hostindependent. 17 We have further confirmed this finding in iNOSKO mice. As shown in Figure 1A , only cisplatintreated ascites expressed 43 Ϯ 5.1% (C57BL6 WT mice) and 52 Ϯ 4.6% (C57BL6 iNOSKO mice) of CAT transgene when a complex of pUCCMVCAT plasmid DNA/liposomes was injected i.p. The statistical difference of CAT gene expression in WT and KO mice was not significant. The ascites of animals treated with either cisplatin or CAT DNA/liposome complex alone were not transfectable. Figure 1B To examine the expression of IFN-␥ gene on the production of NO in ascites, we measured the amount of NO in the tumor. As expected, iNOSKO mice treated with both cisplatin and liposomal IFN-␥ gene did not produce a significant level of NO (12.1 Ϯ 4.5 M), although WT mice receiving both cisplatin and liposomal IFN-␥ gene produced significant amounts of NO (113.7 Ϯ 17.9 M), measured as nitrite plus nitrate level (Fig 2) . The ascites of WT or iNOSKO animals treated with PBS and vector, PBS and liposomal IFN-␥ gene, or cisplatin and vector also did not produce significant amounts of NO.
To test whether the therapeutic benefit of IFN-␥ transduction in MOT, in conjunction with cisplatin, is mediated by a cytotoxic NO molecule, the survival of WT mice (Fig 3A) and iNOSKO mice (Fig 3B) was determined in four different treatment groups. iNOS KO mice treated with liposomal IFN-␥ plasmid DNA Figure 1 . Expression of transgene in MOT ascitic tumors grown in C57BL6 WT and C57BL6 iNOSKO mice. A: CAT reporter gene expression. To examine the expression level of CAT gene in ascites, mice bearing tumors were injected i.p. with either PBS or cisplatin (7 mg/kg). After 1 week, the mice were injected i.p. with either PBS or a complex of plasmid pUCCMVCAT (200 g) and DC-chol liposome (200 nmol). Animals were sacrificed 3 days later, and the tumors were processed. A total of 100 g of protein extract of each sample was then assayed for CAT activity. B: IFN-␥ gene expression. Either the empty vector pBCMGNeo or pBCMGNeo-mIFN-␥ (200 g) with DC-chol liposome (200 nmol) was injected i.p. into tumor-bearing mice, as described in (A). Ascites were collected and centrifuged to obtain ascitic fluid for the measurement of IFN-␥ activities (see Materials and Methods). Each data point is the mean Ϯ SD from three animals.
after receiving cisplatin once every 5 days for 4 weeks after a single injection of cisplatin died of tumors within 11-62 days. However, WT mice treated with liposomal IFN-␥ DNA after cisplatin treatment once every 5 days for 4 weeks after a single injection of cisplatin did not develop tumors and survived for at least 80 days. The surviving mice were maintained without further treatment for 2 months. All mice receiving the empty expression vector, cisplatin, or IFN-␥ DNA/liposome complex alone had a pronounced abdominal mass at day 16 and died 13-39 days after MOT transplantation. As ϳ88% of C57BL6 mice grew the MOT ascitic tumors (ϳ12% rejection; see Table 1 ), we excluded 12% of animals not having tumors for the therapy. Thus, the antitumoral effect of the combined cisplatin and liposomal IFN-␥ gene therapy is indeed due to NO, a major effector for macrophage-mediating tumor cell killing.
DISCUSSION
We have investigated the potential of NO as a chemotherapeutic agent in advanced drug-resistant ovarian cancer using a novel gene therapy protocol. This protocol consists of delivering genes that mediate the formation of free radicals in the peritoneal cavity, in conjunction with cisplatin, to enhance transgene expression and antitumoral activity. Thus, cisplatin can be used simultaneously as a cytotoxic agent, a macrophage activator, and a transduction facilitator specific to tumor cells. Other chemotherapeutic agents, including doxorubicin, paclitaxel, etoposide, etc., can be also used. 17 NO is an important cytostatic/cytolytic mediator for tumor cell killing in vitro and in vivo; it inhibits the trichloroacetic acid cycle, mitochondrial respiration, DNA synthesis, and DNA repair enzymes, 18 -20 and also induces apoptosis. 21 Numerous studies have reported that IFN-␥ activates immune cells such as macrophages Figure 2 . NO production in C57BL6 WT and C57BL6 iNOSKO mice. Mice bearing MOT tumors were injected i.p. with PBS or cisplatin (7 mg/kg). After 1 week, the mice were injected i.p. with either the empty vector (pBCMGNeo) or pBCMGNeo-mIFN-␥ (200 g) complexed with DC-chol liposome (200 nmol). After 3 days, the ascites were collected and centrifuged. The supernatant (ascitic fluid) was used for the measurement of NO as described previously. 13 Each data point is the mean Ϯ SD from three animals. and produces cytostatic or cytolytic NO and TNF-␣ in vitro and in vivo. 22, 23 The apparently high rate of transduction of IFN-␥ to MOT cells in vivo facilitated by prior cisplatin treatment was curative, which was the result of IFN-␥ activation of iNOS in macrophages and the production of NO for killing of tumor cells. 6 In this paper, we have extended our previous work, in which iNOS inhibitor was used to reduce or eliminate NO production. The results confirmed our prior findings that iNOS expression and its subsequent NO production were directly required for this IFN-␥ gene treatment regimen to be effective in a murine ovarian cancer model.
Short-lived free radicals can be endogenously and continuously produced by direct gene transfer into the tumor microenvironment to mediate a localized or regional immune response, which ultimately inhibits tumor growth or kills tumor cells. The studies presented here enabled us to develop a gene therapy strategy to produce NO and to take advantage of the enhanced transfection efficiency associated with prior cisplatin exposure. Furthermore, it has been reported that human macrophages do not produce as much NO in response to IFN-␥ as murine macrophages. 24, 25 Therefore, transfection or introduction directly into the peritoneal cavity of the iNOS gene should generate higher levels of NO and result in a more direct and enhanced therapeutic modality. To make the treatment better, we are also actively investigating ways to enhance NO production and a synergistic tumor cytotoxicity of NO with TNF-␣ for the treatment of drug-resistant human ovarian cancer.
In conclusion, the effectiveness of the cisplatin-based IFN-␥ gene therapy was due to NO produced from iNOS induced in macrophages activated by IFN-␥.
